Virtual Library
Start Your Search
Teresa García
Author of
-
+
P2.04 - Immunooncology (Not CME Accredited Session) (ID 953)
- Event: WCLC 2018
- Type: Poster Viewing in the Exhibit Hall
- Track:
- Presentations: 1
- Moderators:
- Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall
-
+
P2.04-24 - Nivolumab in the "Real World": Are the Results of Clinical Trials Reproducible? (ID 12404)
16:45 - 18:00 | Author(s): Teresa García
- Abstract
Background
It have passed more than two years since the approval of nivolumab in the second or third lines of treatment of non-small cell lung cancer (NSCLC) in advanced or recurrent stages, so that we know the results in patients in our area.
a9ded1e5ce5d75814730bb4caaf49419 Method
The main objective of this study is to analyze the results in a "real" population of different hospitals in Spain since we will be able to compare our results with the once published previously.
We have reviewed 129 patients with NSCLC, advanced or recurrent stages, treated with nivolCutumab either in second and subsequent lines of treatment, after progression to a platinum-based scheme from its expanded use until April 2018, in five hospitals in Spain.
The information was collected retrospectively of clinical, analytical, pathological and treatment characteristics of the patients. Statistical analysis was performed using the SPSS software vs 21.0, considering the statistical significance if p <0.05
4c3880bb027f159e801041b1021e88e8 Result
With a median follow-up of 6 months (0-31), the overall survival (OS) was 9 months (5.86-12.14).
8eea62084ca7e541d918e823422bd82e Conclusion
Patients with ECOG 0-1 presented a median OS of 11 months compared to 3 months of median OS in patients with ECOG 2 (p: 0.001)
If the response to previous treatment was complete response, partial response or stabilization of the disease, they will have a median OS of 12 months compared to 6 months if the best response was progression (p: 0.002).
There is also a statistically significant difference in terms of overall survival in relation to the existence of toxicity for immunotherapy or not (median of 13 versus 6 months p: 0.004).
The overall survival of patients who had progressed beyond 6 months after the start of treatment with prior chemotherapy was significantly greater than patients who had progressed in the first 6 months after the start of chemotherapy (median of 4 months versus median of 13 months, p: 0.001)
Immunotherapy has come to stay taking part of the usual clinical practice of patients with lung cancer. The results obtained in our population are comparable to those previously published, with an important group of patients that responded to immunotherapy or stabilized even for a long time. However, we highlight that also there is a percentage of patients, who progress early. We see fundamental to find or recognize, not just the ideal biomarker that helps to predict response, but those clinical characteristics that can make us presage a poor result.
6f8b794f3246b0c1e1780bb4d4d5dc53